378 related articles for article (PubMed ID: 32058205)
21. Sarcoma of the prostate: a single institutional review.
Janet NL; May AW; Akins RS
Am J Clin Oncol; 2009 Feb; 32(1):27-9. PubMed ID: 19194120
[TBL] [Abstract][Full Text] [Related]
22. Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience.
Bergeron C; Jenney M; De Corti F; Gallego S; Merks H; Glosli H; Ferrari A; Ranchère-Vince D; De Salvo GL; Zanetti I; Chisholm J; Minard-Colin V; Rogers T; Bisogno G;
Eur J Cancer; 2021 Mar; 146():21-29. PubMed ID: 33567392
[TBL] [Abstract][Full Text] [Related]
23. Primary chemotherapy for children with rhabdomyosarcoma of the 'special pelvic' sites: is preservation of the bladder possible?
Kamii Y; Taguchi N; Tsunematsu Y; Kakizawa Y; Saeki M; Honna T; Nakano M; Hashizume K; Komuro H; Bessho F
J Pediatr Surg; 1994 Mar; 29(3):461-4. PubMed ID: 8201521
[TBL] [Abstract][Full Text] [Related]
24. Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy.
Bisogno G; Fuchs J; Dasgupta R; Ferrari A; Haduong JH; Rogers T; Walterhouse DO; Coppadoro B; Xue W; Vokuhl C; Hawkins DS; Seitz G; Merks JHM; Sparber-Sauer M; Venkatramani R
Cancer; 2022 Dec; 128(23):4150-4156. PubMed ID: 36250420
[TBL] [Abstract][Full Text] [Related]
25. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
26. Children with vesical rhabdomyosarcoma (RMS) treated by partial cystectomy with neoadjuvant or adjuvant chemotherapy, with or without radiotherapy. A report from the Intergroup Rhabdomyosarcoma Study (IRS) Committee.
Hays DM; Raney RB; Wharam MD; Wiener E; Lobe TE; Andrassy RJ; Lawrence W; Johnston J; Webber B; Maurer HM
J Pediatr Hematol Oncol; 1995 Feb; 17(1):46-52. PubMed ID: 7743237
[TBL] [Abstract][Full Text] [Related]
27. [Rhabdomysarcoma and combined treatment in oral and maxillofacial regions].
Feng G; Wang DZ; Zheng GY; He J
Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Apr; 22(2):129-31. PubMed ID: 15190796
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
29. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.
Raney RB; Stoner JA; Walterhouse DO; Andrassy RJ; Donaldson SS; Laurie F; Meyer WH; Qualman SJ; Crist WM;
Pediatr Blood Cancer; 2004 Jun; 42(7):618-25. PubMed ID: 15127417
[TBL] [Abstract][Full Text] [Related]
30. Rhabdomyosarcoma of the tongue.
Doval DC; Kannan V; Acharya RS; Mukherjee G; Shenoy AM; Bapsy PP
Br J Oral Maxillofac Surg; 1994 Jun; 32(3):183-6. PubMed ID: 8068593
[TBL] [Abstract][Full Text] [Related]
31. The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group.
Hayes-Jordan A; Stoner JA; Anderson JR; Rodeberg D; Weiner G; Meyer WH; Hawkins DS; Arndt CA; Paidas C;
J Pediatr Surg; 2008 May; 43(5):831-6. PubMed ID: 18485948
[TBL] [Abstract][Full Text] [Related]
32. Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review.
Treetipsatit J; Kittikowit W; Zielenska M; Chaipipat M; Thorner PS; Shuangshoti S
Pediatr Dev Pathol; 2009; 12(5):383-9. PubMed ID: 19175284
[TBL] [Abstract][Full Text] [Related]
33. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
34. Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India.
Roy S; Pathy S; Mohanti BK; Chander S; Biswas A
J Pediatr Hematol Oncol; 2017 Mar; 39(2):e62-e68. PubMed ID: 28060113
[TBL] [Abstract][Full Text] [Related]
35. Embryonal rhabdomyosarcoma of the uterine cervix.
Koukourakis GV; Kouloulias V; Zacharias G; Maravelis G; Papadimitriou C; Platoni K; Gouliamos A
Clin Transl Oncol; 2009 Jun; 11(6):399-402. PubMed ID: 19531457
[TBL] [Abstract][Full Text] [Related]
36. Rhabdomyosarcoma of the oral and maxillofacial region in Jordanians: a retrospective analysis.
Al-Khateeb T; Bataineh AB
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 May; 93(5):580-5. PubMed ID: 12075208
[TBL] [Abstract][Full Text] [Related]
37. Rhabdomyosarcoma with unknown primary tumor site: A report from European pediatric Soft tissue sarcoma Study Group (EpSSG).
Affinita MC; Merks JHM; Chisholm JC; Haouy S; Rome A; Rabusin M; Brennan B; Bisogno G
Pediatr Blood Cancer; 2022 Dec; 69(12):e29967. PubMed ID: 36094298
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
[TBL] [Abstract][Full Text] [Related]
39. Is alveolar histotype a prognostic factor in paratesticular rhabdomyosarcoma? The experience of Italian and German Soft Tissue Sarcoma Cooperative Group.
Ferrari A; Bisogno G; Casanova M; Brecht IB; Alaggio R; Cecchetto G; Provenzi M; Koscielniak E; Treuner J; Carli M
Pediatr Blood Cancer; 2004 Feb; 42(2):134-8. PubMed ID: 14752876
[TBL] [Abstract][Full Text] [Related]
40. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
